Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Number needed to treat in indirect treatment comparison.
Guyot P, Cheng W, Tremblay G, Copher R, Burnett H, Li X, Makin C. Guyot P, et al. J Comp Eff Res. 2018 Mar;7(3):259-269. doi: 10.2217/cer-2017-0023. Epub 2018 Mar 14. J Comp Eff Res. 2018. PMID: 29537878 Free article.
Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020).
Bateman ED, Khan AH, Xu Y, Guyot P, Chao J, Kamat S, Rowe P, Burnett H, Msihid J, Weinreich DM, Pavord ID. Bateman ED, et al. Among authors: guyot p. Respir Med. 2022 Jan;191:106106. doi: 10.1016/j.rmed.2020.106106. Epub 2020 Aug 5. Respir Med. 2022. PMID: 32839071 Free article. No abstract available.
Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, Xu Y, Chuang CC, Neupane B, Msihid J, Mannent LP, Guyot P, Kamat S. Peters AT, et al. Among authors: guyot p. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2461-2471.e5. doi: 10.1016/j.jaip.2021.01.031. Epub 2021 Feb 4. J Allergy Clin Immunol Pract. 2021. PMID: 33548517 Free article.
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A, Smare C, Chen CI, Venkatachalam M, Keeping S, Atsou K, Xu Y, Wilson F, Guyot P, Chan K, Glowienka E, Konidaris G. Kuznik A, et al. Among authors: guyot p. Value Health. 2022 Feb;25(2):203-214. doi: 10.1016/j.jval.2021.08.009. Epub 2021 Oct 16. Value Health. 2022. PMID: 35094793 Free article.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Freemantle N, et al. Among authors: guyot p. Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105024. doi: 10.1177/17588359221105024. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35747163 Free PMC article.
62 results